Is Hims & Hers Stock in Trouble?
Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Is Hims & Hers ...
How Ozempic Has Forever Changed How Much People Spend on Food, According to a New Cornell University Study
Ozempic doesn't just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...
Novo Nordisk, other firms meet Danish PM to discuss Trump tariff threats
Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
Novo Nordisk, other companies meet Danish prime minister following Trump's Greenland threat
COPENHAGEN - The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's ...
Novo Nordisk, other companies to meet Danish prime minister following Trump's Greenland threat
The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...
Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
The CEO of Crunch Fitness doesn’t think there’s such a thing as work-life balance: ‘That’s for somebody who’s not fully committed’
His time in service has informed his key values: commitment, tirelessness, perfectionism, and discipline. When he’s not ...
pharmaphorum22h
Sought-after obesity drug Wegovy backed for NHS use
Novo Nordisk’s weekly injectable drug Wegovy, which can help people lose more than 10% of their body weight, has been cleared for use on the NHS in England by cost-effectiveness agency NICE.